Literature DB >> 1677684

Quantitation of human immunodeficiency virus in vertically infected infants and children.

A Alimenti1, K Luzuriaga, B Stechenberg, J L Sullivan.   

Abstract

We used a quantitative human immunodeficiency virus, type 1 (HIV-1) culture method to determine whether there is a relationship between the amount of replicating virus in the blood of vertically infected children and the relatively short latency period before development of symptomatic disease in these children. HIV-1 titers were determined by end point dilution in the peripheral blood mononuclear cells and the plasma of 30 infected (CDC class P1 and P2), 36 indeterminate (CDC class PO), and 19 uninfected (CDC class P3) infants and children born to HIV-1 seropositive mothers. HIV-1 was recovered from 35 (90%) of 39 PBMC cultures and 23 (60%) of 38 plasma cultures of infected patients not receiving antiretroviral therapy. The mean HIV-1 titers tended to be higher in patients with more advanced disease (P2, D, E, or F: 1760 TCID/10(6) PBMC, 460 TCID/ml plasma) than in asymptomatic or mildly symptomatic patients (P1; P2, A or C: 90 TCID/10(6) PBMC; 60 TCID/ml plasma). A poor correlation between HIV-1 titers and serum p24 antigen levels was found. No correlation was observed between viral titers and relative or absolute numbers of CD4 lymphocytes. Plasma virus titers were lower in 9 patients receiving zidovudine (ZDV) therapy (mean 2 TCID/ml) than in untreated patients of similar clinical status. The viral titers measured in the blood of vertically infected infants and children were on the same order of magnitude as the viral titers measured in HIV-infected adults. We conclude that the relatively rapid progression to symptomatic disease of the majority of vertically infected patients is not due to a higher load of replicating virus in blood.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1677684     DOI: 10.1016/s0022-3476(05)80731-0

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  8 in total

1.  Diagnosis of human immunodeficiency virus infection using citrated whole blood.

Authors:  U K Sharma; H F Song; F F Willingham; J Hannig; C Flexner; H Farzadegan; C Nicolau; D H Schwartz
Journal:  Clin Diagn Lab Immunol       Date:  1997-05

2.  Prognostic value of immunological data, in vitro antibody production, and virus culture in vertical infection with HIV-1.

Authors:  M C García Rodriguez; I Bates; I de José; F Hawkins; R Martinez-Zapico; A Ferreira; G Fontán
Journal:  Arch Dis Child       Date:  1995-06       Impact factor: 3.791

3.  Human immunodeficiency virus type 1 genetic evolution in children with different rates of development of disease.

Authors:  S Ganeshan; R E Dickover; B T Korber; Y J Bryson; S M Wolinsky
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

4.  Survival of human immunodeficiency virus (HIV), HIV-infected lymphocytes, and poliovirus in water.

Authors:  B E Moore
Journal:  Appl Environ Microbiol       Date:  1993-05       Impact factor: 4.792

5.  Effective use of frozen donor peripheral blood mononuclear cells for human immunodeficiency virus type 1 isolation from vertically infected pediatric patients.

Authors:  M O Paul; S Tetali; S Pahwa
Journal:  J Clin Microbiol       Date:  1994-05       Impact factor: 5.948

6.  Quantification of human immunodeficiency virus in plasma by RNA PCR, viral culture, and p24 antigen detection.

Authors:  I Van Kerckhoven; K Fransen; M Peeters; H De Beenhouwer; P Piot; G van der Groen
Journal:  J Clin Microbiol       Date:  1994-07       Impact factor: 5.948

7.  Simian immunodeficiency virus (SIV) infection of infant rhesus macaques as a model to test antiretroviral drug prophylaxis and therapy: oral 3'-azido-3'-deoxythymidine prevents SIV infection.

Authors:  K K Van Rompay; M L Marthas; R A Ramos; C P Mandell; E K McGowan; S M Joye; N C Pedersen
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

8.  Placental Hofbauer cells assemble and sequester HIV-1 in tetraspanin-positive compartments that are accessible to broadly neutralizing antibodies.

Authors:  Erica L Johnson; Hin Chu; Siddappa Nagadenahalli Byrareddy; Paul Spearman; Rana Chakraborty
Journal:  J Int AIDS Soc       Date:  2015-01-22       Impact factor: 5.396

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.